Objectives: Simple blood markers derived from routine hematology or biochemistry have been reported to be prognostic factors of overall survival (OS) in cancer patients [1,2]. However, most studies only use baseline (BSL) values. The only longitudinal biomarker that has been extensively used and modeled to date is tumor size kinetics…
Read moreObjectives: Modeling tumor growth dynamics in different tumor types and under various therapeutic interventions has been an active area of…
Read moreObjectives: Prediction of survival curves, overall survival (OS) and progression-free survival (PFS), based on pre-trained models could help to refine…
Read moreObjectives: FAP-4-1BBL is a T-cell bispecific antibody exerting 4-1BB costimulation only while simultaneously bound to the Fibroblast Activation Protein (FAP)…
Read moreIntroduction: Bevacizumab (BV), an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been approved for the treatment of metastatic…
Read moreContext: In oncology, a common marker of tumor burden is the Sum of Longest Diameters (SLD) of target lesions, and…
Read moreBackground C-reactive protein (CRP), a marker of inflammation, positively correlates with disease aggressiveness and poor prognosis in advanced cancers including…
Read moreObjectives: Immune checkpoint inhibitors (ICIs) such as ipilimumab (CTLA4 inhibitor), nivolumab or pembrolizumab (PD1 inhibitors) have revolutionized cancer therapy with…
Read moreObjectives: In oncology drug development, rapid dose optimization is pivotal to allow timely patient benefit. For this, the FDA’s Project…
Read moreObjectives: Immuno-oncology (IO), based on the activation of the endogenous anti-tumor immune response, is a growing strategy in cancer treatment….
Read more